You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)

    SBC: Inbios International Inc            Topic: NIAID

    Project Summary Ebolavirus spp. cause a severe hemorrhagic fever known as Ebola virus disease (EVD). EVD is a serious public health concern, both as an emerging infectious disease and a potential biothreat. The 2013-2016 Ebola pandemic in West Africa brought global attention to the challenges associated with controlling an Ebola. The ongoing outbreak in the Democratic Republic of Congo, which rece ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. CBTpro: Scaling up CBT for psychosis using simulated patients and spoken language technologies

    SBC: Lyssn.IO, INC.            Topic: 104

    Psychosis resulting from schizophrenia spectrum disorders and major mood disorders is one of the most disabling health concerns worldwide. Evidence-based psychotherapeutic interventions are recommended as standard of care by national psychosis treatment guidelines but are rarely accessible. Cognitive Behavioral Therapy for psychosis (CBTp) is the most well-researched psychotherapy for psychotic di ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Development of wearable technology to enable therapy personalization of 177Lu DOTATATE for neuroendocrine tumors

    SBC: PRECISION SENSING LLC            Topic: 102

    For patients with metastatic, somatostatin-receptor-2 (SSTR2) positive neuroendocrine tumors (NETs), targeted therapy using 177Lu-DOTATATE greatly increases progression-free survival (PFS), as shown in the NETTER-1 trial. PFS at month 20 was 65.2% (95% CI, 50.0 - 76.8) for midgut NETs treated with 177Lu- DOTATATE alone compared to 10.8% (95% CI, 3.5 - 23.0) in a control group receiving 60 mg octre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. New Inhibitors of HIV latency reactivation

    SBC: Ithax Pharmaceuticals Inc            Topic: NIAID

    ABSTRACTCompany - Ithax Pharmaceutical is a new spin-off biotechnology company, located in Seattle, focused on developing proprietary small molecule chemistry to target RNA. The experience of its founders spans virology, drug design and RNA structure and function, and gives it a unique technological expertise in the RNA-targeting space. Their commercial expertise includes the successful founding, ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Antioxidant enzyme-loaded Pro-NP for treatment of TBI.

    SBC: ProTransit Nanotherapy, LLC            Topic: 106

    ABSTRACT Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide and comes with a significant economic burden associated with emergency room visits and hospitalizations. Oxidative stress- mediated secondary injury post-TBI is a considerable risk factor for mortality and long-term impairment. Immediately following TBI, a cascade of biological responses leads to i ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization

    SBC: Breezmed            Topic: 104

    ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Small molecule inhibitors of oncogenic miR-21

    SBC: Ithax Pharmaceuticals Inc            Topic: 102

    Project Summary: Company development - Ithax Pharmaceuticals is a new spin-off biotechnology company located in Seattle and focused on developing small drug-like molecules that target non-coding RNAs in cancer and other chronic diseases. The experience of its founders’ spans drug design, RNA structure, cancer biology and biotech management, and includes the successful spin offs of several biotec ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Laser-based in-situ, real-time imaging of Temperature in Detonation Environments

    SBC: ExMat Research, Inc.            Topic: DTRA19B001

    ExMat Research proposes to develop a hardened and cost-scalable laser-based temperature diagnostic system capable of spatially quantifying the localized temporal evolution of temperature in a detonation environment. During Phase I, we will attempt to determine the technical feasibility of the proposed concept. While ExMat Research will be guiding and overseeing the overall project, Washington Stat ...

    STTR Phase I 2020 Department of DefenseDefense Threat Reduction Agency
  9. Development and Commercialization of a Sample Preparation System for Time Resolved Cryo-Electron Microscopy

    SBC: Hummingbird Precision Machine Co.            Topic: 400

    Project Summary Project Title: Development and Commercialization of a Sample Preparation System for Time Resolved Cryo-Electron Microscopy Company Name: Hummingbird Precision Machine Co., dba Hummingbird Scientific Principal Investigator: Norman Salmon Summary: Cryo-electron microscopy (cryo-EM) is a powerful technique for imaging biological molecules in which samples are preserved in a frozen, hy ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Translational development of specialized NK cells for cancer immunotherapy

    SBC: Indapta Therapeutic            Topic: 102

    Project Summary Abstract The annual incidence of head and neck cancers worldwide is more thancases with arounddeaths each yearand it is estimated that inthere will benew cases of non Hodgkin lymphoma with an estimateddeaths this yearIn this proposalwe describe a strategy to use a novel subset of natural killer cellsg NK cellsallogeneically for cancer therapyWe hypothesize that expansion and adopti ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government